Exp Clin Endocrinol Diabetes 2020; 128(10): 654-662
DOI: 10.1055/a-1079-4711
Article

Angiopoietin 2 and Neuropeptide Y are Associated with Diabetic Kidney Disease in Type 1 Diabetes Mellitus

1   Faculty of Medicine, University of Latvia, Riga, Latvia
,
Juris Stefanovics
1   Faculty of Medicine, University of Latvia, Riga, Latvia
,
Gita Gersone
2   Faculty of Medicine, Department of Human Physiology and Biochemistry, Riga Stradins University, Latvia
,
Leonora Pahirko
4   Faculty of Physics, Mathematics and Optometry, University of Latvia, Riga, Latvia
,
Janis Valeinis
4   Faculty of Physics, Mathematics and Optometry, University of Latvia, Riga, Latvia
,
Sanita Kalva-Vaivode
1   Faculty of Medicine, University of Latvia, Riga, Latvia
,
Vita Rovite
5   Latvian Biomedical Research and Study Centre, Riga, Latvia
,
Leons Blumfelds
2   Faculty of Medicine, Department of Human Physiology and Biochemistry, Riga Stradins University, Latvia
,
Valdis Pirags
1   Faculty of Medicine, University of Latvia, Riga, Latvia
3   Pauls Stradins Clinical University Hospital, Riga, Latvia
5   Latvian Biomedical Research and Study Centre, Riga, Latvia
,
Peteris Tretjakovs
2   Faculty of Medicine, Department of Human Physiology and Biochemistry, Riga Stradins University, Latvia
› Author Affiliations
Funding Sources: Recruitment of patients was supported by the Latvian State Genome database project and Latvian Association of Endocrinology. Reagents were supplied in terms of a project of the University of Latvia: “Research of biomarkers and natural substances for acute and chronic diseases’ diagnostics and personalised treatment”.

Abstract

Background Serum angiopoietin 2 levels have been associated with endothelial dysfunction and diabetic kidney disease. Derangements in autonomous nervous system lead to increased production of vasoconstrictory and angiogenic mediators such as norepinephrine and neuropeptide Y and are associated with increased risk of microvascular complications.

Aim To investigate associations between angiopoietin 2, neuropeptide Y and diabetic kidney disease in patients with type 1 diabetes mellitus.

Methods 289 patients with type 1 diabetes mellitus duration > 1 year were included. Patients were stratified according to presence of diabetic nephropathy (macroalbuminuria, estimated glomerular filtration rate<60 ml/min/1.73 m2 or end-stage renal disease). Angiopoietin 2 was measured by Luminex technology. Neuropeptide Y was measured by ELISA.

Results Patients with diabetic nephropathy had significantly increased levels of angiopoietin 2 (4020.5 (2172.4–5778.1) pg/ml vs. 2001.0 (1326.7–2862.7) pg/ml) and neuropeptide Y (18.22 (14.85–21.85) ng/ml vs. 12.91 (9.96–17.07) ng/ml). Higher levels of angiopoietin 2 and neuropeptide Y were observed also in patients with arterial hypertension. Angiopoietin 2 and neuropeptide Y correlated significantly (ρ=0.245, p<0.001). Both biomarkers were significant predictors of estimated glomerular filtration rate and diabetic nephropathy in univariate regression models. In the fully adjusted regression models and after application of a stepwise selection regression method, angiopoietin 2 demonstrated a stronger predictive power for diabetic nephropathy compared to neuropeptide Y.

Conclusion Diabetic nephropathy is associated with increased serum concentrations of angiopoietin 2 (marker of endothelial dysfunction) and neuropeptide Y (marker of sympathetic activity) in type 1 diabetes. Angiopoietin 2 is a more potent predictor of diabetic nephropathy compared to neuropeptide Y.



Publication History

Received: 10 May 2019
Received: 04 December 2019

Accepted: 09 December 2019

Article published online:
20 January 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany